CN119451982A - 结合her-3和her-2或egfr的双特异性抗体 - Google Patents

结合her-3和her-2或egfr的双特异性抗体 Download PDF

Info

Publication number
CN119451982A
CN119451982A CN202380025034.3A CN202380025034A CN119451982A CN 119451982 A CN119451982 A CN 119451982A CN 202380025034 A CN202380025034 A CN 202380025034A CN 119451982 A CN119451982 A CN 119451982A
Authority
CN
China
Prior art keywords
domain
seq
antibody
fab
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380025034.3A
Other languages
English (en)
Chinese (zh)
Inventor
E·朱科夫斯基
P-E·杰拉德
C·拉伯雷特
R·埃米利亚
T·查德斯
A·佩莱格里恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Biomunex Pharmaceuticals
Institut Regional du Cancer de Montpellier
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Biomunex Pharmaceuticals
Institut Regional du Cancer de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Montpellier, Biomunex Pharmaceuticals, Institut Regional du Cancer de Montpellier filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of CN119451982A publication Critical patent/CN119451982A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380025034.3A 2022-03-02 2023-03-01 结合her-3和her-2或egfr的双特异性抗体 Pending CN119451982A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305242 2022-03-02
EP22305242.4 2022-03-02
PCT/EP2023/055243 WO2023166098A1 (en) 2022-03-02 2023-03-01 Bispecific antibodies binding to her-3 and to either her-2 or egfr

Publications (1)

Publication Number Publication Date
CN119451982A true CN119451982A (zh) 2025-02-14

Family

ID=80930221

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380025034.3A Pending CN119451982A (zh) 2022-03-02 2023-03-01 结合her-3和her-2或egfr的双特异性抗体

Country Status (9)

Country Link
US (1) US20250282892A1 (https=)
EP (1) EP4486774A1 (https=)
JP (1) JP2025510539A (https=)
KR (1) KR20240154641A (https=)
CN (1) CN119451982A (https=)
AU (1) AU2023228330A1 (https=)
CA (1) CA3244947A1 (https=)
TW (1) TW202342538A (https=)
WO (1) WO2023166098A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2603527A1 (en) 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP5786839B2 (ja) 2012-12-05 2015-09-30 株式会社デンソー エポキシ樹脂組成物および接着構造体の製造方法
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains

Also Published As

Publication number Publication date
JP2025510539A (ja) 2025-04-15
AU2023228330A1 (en) 2024-09-19
CA3244947A1 (en) 2023-09-07
KR20240154641A (ko) 2024-10-25
EP4486774A1 (en) 2025-01-08
TW202342538A (zh) 2023-11-01
WO2023166098A1 (en) 2023-09-07
US20250282892A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
CN113480656B (zh) 抗ror1抗体
KR102360742B1 (ko) Egfr 및 her2 를 표적하는 이특이적 항체
AU2017226510C1 (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
KR102361412B1 (ko) Cd38 및 pd-l1에 대한 결합 분자
EA038654B1 (ru) Новое антитело к мезотелину и содержащая его композиция
CN103403025A (zh) 单价抗原结合蛋白
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
US20250382386A1 (en) Anti-alk-1 antibody and use thereof
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
US20250282892A1 (en) Bispecific antibodies binding to her-3 and to either her-2 or egfr
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
WO2025117872A1 (en) Bispecific antibody-like protein and methods of making and using thereof
TW202502823A (zh) Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途
EP4676960A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184810A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
EP4676962A1 (en) Anti-cldn6 antibodies and methods of use
KR20250135302A (ko) 항-cmet 항체 및 사용 방법
TW202540199A (zh) 靶向her2及her3之雙特異性四價抗體
HK40061499A (en) Anti-ror1 antibodies
CN120530135A (zh) 抗b7h3抗体和使用方法
CN117586413A (zh) 异多聚体蛋白质及其制备方法
HK1191343A (zh) 单价抗原结合蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination